BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220921
DTEND;VALUE=DATE:20220923
DTSTAMP:20260516T001518
CREATED:20220404T083554Z
LAST-MODIFIED:20220404T083554Z
UID:33687-1663718400-1663891199@www.pharmajournalist.com
SUMMARY:Oligonucleotide Therapeutics and Delivery Conference 2022
DESCRIPTION:Part of the 13th annual RNA Therapeutic series of events\nSMi’s 2nd Annual Conference \nOligonucleotide Therapeutics and Delivery Conference 2022\nDate: 21st – 22nd September 2022\nLocation: London\, UK\nWebsite: www.oligonucleotide.co.uk/PharmaJournalist \nAdvancements in extra-hepatic delivery of oligonucleotides \nThe Oligonucleotide Therapeutics and Delivery conference reveals the latest in oligonucleotide discovery and delivery\, with presentations on targeted delivery mechanisms\, oligonucleotide chemistries and important clinical advances. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of oligonucleotides with case studies surrounding the discovery and development of oligonucleotide therapeutics as well as CMC and regulatory standpoints. The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. \nEstablished on the success of our RNA Therapeutics series\, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments. \nBenefits of attending: \n\nListen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials\nDeepen your understanding of oligonucleotide therapeutic delivery and explore the latest innovations in extrahepatic oligonucleotide delivery and target specificity\nUnderstand the regulatory and CMC environment surrounding oligonucleotide therapeutic development\nExplore developments in oligonucleotide chemistries and examine developments in novel applications of antisense oligonucleotides and siRNA\nEngage in the latest innovations in oligonucleotide therapeutics such as utilising AI machine learning to drive the discovery of novel therapeutics\n\nPlus\, two interactive half day pre-conference workshops on 20th September 2022: \n\nOligonucleotide Therapies- Overcoming The Challenges Of Delivery led by Nick Lench\, Executive Director\, NATA\, Martin Kerr\, Head of Business Development & Partnerships\, Nucleic Acid Therapy Accelerator\, Ritwick Sawakar\, MRC Investigator\, MRC Toxcology Unit\, University Of Cambridge\nManaging CMC Activities For The Development Of Oligonucleotide Therapeutics led by Mia Kiistala\, CEO/Owner/Principal Consultant\, Aurora CMC Consulting \n\nCHAIRS FOR 2022: \n\nEkkehard Leberer\, Senior Life Sciences Consultant\, Elbicon\njimmy Weterings\, Principal Scientist\, AstraZeneca \n\nFEATURED 2022 SPEAKERS INCLUDE:  \n\nShalini Anderson\, Vice President Oligonucleotide Discovery\,AstraZeneca\nHeinrich Haas\, Vice President RNA Formulation & Drug Delivery\, BioNTech\nTamar Grossman\, Global Head of RNA and Targeted Therapeutics\, Janssen pharmaceuticals\nSarahTabrizi\,Director of UCL Huntington’s disease centre\, UCL Institute of Neurology\nMacarena Hernandez-Jimenez\, Chief Scientific Officer\, AptaTargets\nDavid Evans\, Chief Scientific Officer\, Sirnaomics\nNick Lench\, Executive Director\, Nucleic Acid Therapy Accelerator\nBart Anderson\,Senior Director of R&D\, Exicure\n\nWho should attend: \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of: \n\nRNA Biology/Discovery\nNovel Therapeutic Modalities\nInnovation Technologies\nC-level Scientific Executives\nFormulation and Drug Delivery\nClinical Research and Development\nCell Biology\n\nEARLY-BIRD RATES: \n\nBOOK BY 29TH APRIL AND SAVE £400\nBOOK BY 31ST MAY AND SAVE £300\nBOOK BY 30TH JUNE AND SAVE £200\n\nAdditional Contact Info: \nT: +44 (0)20 7827 6154 \nE: ngaloria@smi-online.co.uk \nLinkedIn: SMi Pharma \nTwitter: @SMiPharma | #SMiOligonucleotides  \nKeywords: \nSmall interfering RNA\, siRNA\, Antisense therapy\, DNA\, RNA\, nucleic acid\, mRNA\, Micro RNA\, RNA-induced silencing complex\, RISC\, Aptamers\, oligonucleotide\, peptide molecules\, Immunogenicity\, Drug pipeline\, short interfering RNA\, silencing RNA\, RNA interference\, RNAi\, mRNA degradation \nHashtags:  \n#SmallinterferingRNA\, #siRNA\, #Antisensetherapy\, #DNA\, #RNA\, #nucleicacid\, #mRNA\, #MicroRNA\, #RNAinducedsilencingcomplex\, #RISC\, #Aptamers\, #oligonucleotide\, #peptidemolecules\, #Immunogenicity\, #Drugpipeline\, #shortinterferingRNA\, #silencingRNA\, #RNAinterference\, #RNAi\, #mRNAdegradation
URL:https://www.pharmajournalist.com/event/oligonucleotide-therapeutics-and-delivery-conference-2022/
LOCATION:London\, UK
ORGANIZER;CN="SMi Events":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220926
DTEND;VALUE=DATE:20220929
DTSTAMP:20260516T001518
CREATED:20220531T070301Z
LAST-MODIFIED:20220531T070301Z
UID:34307-1664150400-1664409599@www.pharmajournalist.com
SUMMARY:4th RAS-Targeted Drug Development Summit
DESCRIPTION:For decades\, RAS has existed as an elusive therapeutic target\, and drugging this high-value oncogene was deemed impossible. Despite this\, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is\, in fact\, druggable and that drugging this protein unlocks a world of successful therapeutic interventions. The future looks bright for treating patients with cancers harboring the RAS mutation. \nThe 4th RAS-Targeted Drug Development Summit returns as the definitive industry dedicated forum for the whole community of individuals committed to targeting RAS. Bigger and better than ever before\, we will unite 300+ experts to showcase 3-days of exclusive\, never shared before data as we delve into accelerating discovery and emerging strategies\, optimizing translation and pre-clinical development\, and advancing the landscape of clinical trials for combinations and monotherapies. \nWith mounting success in targeted RAS drugs\, leading frontiers and experts must unite and continue accelerating the applications of this therapeutic for patients in need.  Through novel data\, expert insight\, and exclusive discussions with global leaders\, we will facilitate vital learnings to progress RAS therapeutics to drug all-mutations from G12C\, G12D\, and G12V. Continuing to advance valuable combination therapies into the clinic\, and finally\, crack resistance to RAS targeted therapeutics. \nAccess the official agenda for more information. \nEarly-bird & team discounts available – Secure your place today.
URL:https://www.pharmajournalist.com/event/4th-ras-targeted-drug-development-summit/
LOCATION:Marriott Burlington\, One Burlington Mall Road\, Burlington\, MA\, 01803\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221003
DTEND;VALUE=DATE:20221006
DTSTAMP:20260516T001518
CREATED:20220623T103213Z
LAST-MODIFIED:20220623T103213Z
UID:34498-1664755200-1665014399@www.pharmajournalist.com
SUMMARY:LEAP TA: Life Sciences 2022
DESCRIPTION:The Definitive Event to Transform Your Internal Impact & Differentiate Your Employer Brand to Attract the in-Demand Biopharma Talent Required to Fast-Track Business Innovation & Growth \nNow in its fourth year\, LEAP TA: Life Sciences is the only forum dedicated to helping established and emerging life sciences organizations operating in the US who are breaking away from traditional TA to develop high functioning TA teams bursting to inspire talent needed to drive mission-critical innovation. \nIt is a unique opportunity to engage in a genuinely disruptive dialogue with your peers around what TA tech tools are really worth the investment and the radical new talent acquisition strategies required to address how life sciences organizations will deal with the fallout of the tight talent market in 2022 and beyond. \nDesigned for anyone with a stake in talent acquisition at the heart of biopharma businesses of all sizes\, those who take part will find out how to rewrite the rules of talent acquisition to balance speed with fit in finding brilliant people to gain a sustainable competitive advantage. \nSo\, whether you work in the newest start-up biotech or the largest big pharma company\, there’s something at this event for you. Secure your place now to save time\, money and add vital efficiencies to your talent acquisition activities. \nTo know more visit: https://bit.ly/3HO1Tdv
URL:https://www.pharmajournalist.com/event/leap-ta-life-sciences-2022/
LOCATION:Embassy Suites by Hilton Boston at Logan Airport\, 207 Porter St\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221004
DTEND;VALUE=DATE:20221007
DTSTAMP:20260516T001518
CREATED:20220610T091530Z
LAST-MODIFIED:20220610T091530Z
UID:34394-1664841600-1665100799@www.pharmajournalist.com
SUMMARY:2nd Rare and Genetic Kidney Drug Development Summit
DESCRIPTION:Uniting industry experts dedicated to accelerating the frontier of transformative therapeutics\, the 2nd Rare & Genetic Kidney Disease Drug Development Summit is the definitive industry forum sharing cross-industry insight to understand genetic drivers of disease\, uncover early biomarkers of efficacy\, and navigate disease specific endpoint development. \nFrom clarifying molecular characteristics to reclassify disease subtypes to enrolling patient cohorts in rare disease populations\, join industry experts in-person from Travere Therapeutics\, FDA\, Sanofi\, Chinook Therapeutics\, Goldfinch Bio\, Takeda\, Regulus Therapeutics\, Otsuka and many more to accelerate life-changing therapeutics for the treatment of ADPKD\, ARPKD\, IgA\, FSGS\, Alport Syndrome. \nTo know more visit: https://ter.li/rzowfh
URL:https://www.pharmajournalist.com/event/2nd-rare-and-genetic-kidney-drug-development-summit/
LOCATION:Hilton Woburn\, 2 Forbes Road\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:(+1) 617 455 4188
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221004
DTEND;VALUE=DATE:20221007
DTSTAMP:20260516T001518
CREATED:20220630T094848Z
LAST-MODIFIED:20220630T094848Z
UID:34555-1664841600-1665100799@www.pharmajournalist.com
SUMMARY:4th Macrophage-directed Therapies Summit
DESCRIPTION:4th Macrophage-directed Therapies Summit\, taking place from 4-6 of October in Boston\, will bring together professionals to accelerate the clinical validation of macrophage-directed therapies\, manipulating and fixing phenotypic plasticity to develop safe\, targeted therapies for oncology\, autoimmunity\, inflammation and beyond. \nJoin your peers in person and delve into: \n\nCD47 targeting and other ‘don’t eat me’ signals\nSafety concerns due to model translatability and dosing\nOptimal combination or monotherapy discovery\n\nYou can view the event guide here: https://ter.li/ezyi0h \nSecure your place at the summit here: https://ter.li/x9p0ua \nWe are looking forward to welcoming you to Boston this October!
URL:https://www.pharmajournalist.com/event/4th-macrophage-directed-therapies-summit/
LOCATION:Crowne Plaza Boston Woburn\, 15 Middlesex Canal Park Dr\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221005
DTEND;VALUE=DATE:20221007
DTSTAMP:20260516T001518
CREATED:20220630T101923Z
LAST-MODIFIED:20220630T102012Z
UID:34567-1664928000-1665100799@www.pharmajournalist.com
SUMMARY:2nd Annual Next Generation Pharmaceutical Cleanroom
DESCRIPTION:2nd Annual Next Generation Pharmaceutical Cleanroom \n5 – 6 October 2022\nLondon\, UK\nhttp://www.nextgen-pharmacleanroom.com/PJwl \nSponsored by Ecolab\, Elis Cleanroom\, Innerspace\, Microgenetics\, Novatek \nCo-Chaired by: Conor Murray\, Chairman\, Irish Cleanroom Society and Connor McMorrow\, Aseptic Lead Cell Therapy\, Takeda  \nAdvances in Pharma 4.0 for an Improved\, Efficient and Contaminant-Free Cleanroom \nSAE Media Group are pleased to announce the 2nd Annual Next Generation Pharmaceutical Cleanroom Conference. An event that focuses on cleanroom technology in the pharmaceutical industry\, the conference will serve to bridge that gap between the two areas while simultaneously providing a unique selling point. \nThis one-of-a-kind meeting will facilitate networking opportunities with key opinion leaders from all areas of pharmaceuticals\, biologicals\, and cleanroom industry experts to explore hot topics within cleanroom design and engineering\, best practices and regulation\, environmental and contamination control\, and pharmaceutical microbiology. \nIn 2025\, the global cleanroom technology market is expected to reach nearly $5 billion. Stringent regulatory standards for product approvals\, technological advancements in cleanrooms\, initiatives taken by private organisations to create awareness regarding cleanroom and growth of the healthcare sector globally are among the few factors expected to drive the market. \nThis event will look in-depth at the significant change that the cleanroom industry is going through. From the new operating practices that keep the product as sterile as possible\, to the developments in technology that are enabling this to happen. Whether through robotics\, automated disinfection\, or data driven environmental monitoring- this conference will highlight the developments that are fundamentally changing the industry. \nEvent Hashtag: #PharmaCleanrooms \nKey Reasons to attend: \n\nLearn how to maximise the latest cleanroom technologies to modernise your contamination control strategy\nMaximise the cost-effectiveness of your cleanroom and navigate best practises for cleanroom design\nOptimise your preparation for upcoming regulatory changes\, including the impending Annex 1\nIncrease your cleanroom availability & accessibility through streamlined approaches to contamination control\n\nWHO SHOULD ATTEND: \nSenior Micro Manager\, QC Manager\, Quality Director\, Clean Room Design Managers\, Design\, Qualify and Testing – Clean Room (across the board)\, Head of Clean Room Technologies\, Head of Compounding Pharmacies\, Head of Clinical Drug Products\, Head of Clinical Medical Device \nView the brochure and to download visit http://www.nextgen-pharmacleanroom.com/PJwl
URL:https://www.pharmajournalist.com/event/2nd-annual-next-generation-pharmaceutical-cleanroom/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221010
DTEND;VALUE=DATE:20221012
DTSTAMP:20260516T001518
CREATED:20220511T084634Z
LAST-MODIFIED:20220511T084634Z
UID:34048-1665360000-1665532799@www.pharmajournalist.com
SUMMARY:SAE Media Group's 3rd Annual Wearable Injectors and Connected Devices Conference
DESCRIPTION:SAE Media Group’s 3rd Annual  \nWearable Injectors and Connected Devices Conference \n10 – 11 October 2022 | London\, UK \nhttp://www.wearable-injectors.co.uk/Pharmajournalist \nThe Latest Innovations In Digital Health And On-Body Drug Delivery For The Pharmaceutical Industry \nSAE Media Group’s 3rd annual Wearable Injectors and Connected Devices Conference will explore on-body device design and development whilst also engaging in the latest advances in connectivity and digital health applications for wearable devices with industry perspectives from big pharma representatives. The conference will consider key developments in the wearable injectors field\, including the enhanced demand for on-body injectors and digitalised health as the need for at home self-administration and routes for delivery of time-dependent\, high volume and viscous drugs grow. \nBenefits of Attending: \n\nEngage with key regulatory updates surrounding digital health and medical devices\nDiscover advances in device design and development for large volume delivery via on-body injectors\nExplore the key drivers of novel drug products for the development for on-body injectors\nHear insights into the growing potential of digital health to improve patient experience and treatment\nDevelop your understanding of design strategies for connectivity and digital health\n\nDelegates will have the opportunity to network with the following companies: \n\nJohnson & Johnson\nBiogen\nAstraZeneca\nMerck KGaA\nNovartis\nNovo Nordisk\nBoehringer Ingelheim\n\nAnd many more!! \nWho Should Attend: \n\nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of:\nDrug-Delivery Developers\nAutoinjectors\nDevice Engineering\nHuman Factors\nInjectables\nPackaging\nRegulatory Affairs\nConnectivity\nMedical Device Data\nNovel Product Technology\nSmart Device Developers\nDevice Safety Solution Providers\nor anyone who works with Wearable Devices/ On-Body Injectors within pharmaceuticals\, biotech\, device developers and solution providers.\n\nThe two-day conference will bring you high-quality insights and industry connections on the latest advances in wearable injectors and connectivity\, and a platform for exchanging ideas. \nFor more information contact: \nNikisha Galoria | Marketing Executive | SAE Media Group \nEmail: ngaloria@smi-online.co.uk \nPhone: +44 (0) 20 7827 6164 \nFollow us on: \nLinkedIn: SAE Media Group Pharma \nTwitter: @SAEMGPharma
URL:https://www.pharmajournalist.com/event/sae-media-groups-3rd-annual-wearable-injectors-and-connected-devices-conference/
LOCATION:London\, UK
ORGANIZER;CN="Hanson Wade":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221011
DTEND;VALUE=DATE:20221014
DTSTAMP:20260516T001518
CREATED:20220617T103229Z
LAST-MODIFIED:20220617T103229Z
UID:34419-1665446400-1665705599@www.pharmajournalist.com
SUMMARY:Reuters Events: Pharma 2022
DESCRIPTION:Comprehensive frameworks for equitable access and accelerated digital transformations are soon to be realized. But progress is slowing\, risking a return to the old model plagued by persistent health disparities. \nTo thrive\, each strategy and tactic must be centred with a whole-human approach\, ensuring an agile\, patient-driven\, technology-enabled change. \nYou must advance intelligent automation\, delivering value-driven content that enhance patient and HCP experiences\, activate new skillsets for field teams to strengthen clinical practices\, whilst collaborating with stakeholders – and competitors – to drastically improve equitable access to the vast galaxy of innovation improving patient outcomes and propelling commercial growth. \nReuters Events: Pharma 2022 (11-13 October\, Nice France – formerly eyeforpharma Barcelona) is the only place where patient experts\, leading solution providers\, and pharma changemakers – from commercial\, marketing\, medical affairs\, patient engagement\, market access and RWE – commit to business transformation as the catalyst for maximum patient impact. \nTo know more visit: https://bit.ly/3xVKqN8
URL:https://www.pharmajournalist.com/event/reuters-events-pharma-2022/
LOCATION:Nice Acropolis Convention Center\, Nice\, France
ORGANIZER;CN="Reuters Events":MAILTO:Matt.atkinson@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221011
DTEND;VALUE=DATE:20221014
DTSTAMP:20260516T001518
CREATED:20220630T100728Z
LAST-MODIFIED:20220630T100728Z
UID:34561-1665446400-1665705599@www.pharmajournalist.com
SUMMARY:10th IMPACCT Real World Evidence Summit
DESCRIPTION:Returning in person for its 10th year anniversary\, the IMPACCT: Real World Evidence Summit will deep dive into the use of RWE for regulatory submissions and improved clinical trial design to help you navigate the regulatory landscape. \nFollowing recent FDA and EMA guidelines\, this comprehensive industry-led forum will address how drug developers can leverage RWE from beginning to end of study\, ensure clinical studies are well-designed\, include appropriate protections for their patients and upload data integrity. \nJoin 100+ senior leaders in RWE\, RWD\, real world analytics experts & epidemiologists from pharma and biotech to take part in this three day summit with over 18 hours of exclusive content. \nTo know more visit: https://ter.li/tymfzh
URL:https://www.pharmajournalist.com/event/10th-impacct-real-world-evidence-summit/
LOCATION:Crowne Plaza Woburn\, 15 Middlesex Canal Park Rd\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221011
DTEND;VALUE=DATE:20221014
DTSTAMP:20260516T001518
CREATED:20220712T103251Z
LAST-MODIFIED:20220713T075908Z
UID:34648-1665446400-1665705599@www.pharmajournalist.com
SUMMARY:3rd Commercializing Flow Chemistry Summit 2022
DESCRIPTION:With the exciting proof-of-concept milestones from Phlow\, commitments from global regulatory agencies\, and breakthroughs from the likes of AbbVie\, AstraZeneca\, Merck and BMS\, over the last 12 months flow chemistry continues to take off at an exponential rate\, further evidenced by the significant investments from CDMOs such as Almac\, Corden Pharma\, Sterling and Cambrex. \nShowcasing the steep progress being made whilst addressing the field’s most front-of-mind challenges to enable the full potential of continuous chemistry to come to fruition\, the 3rd Annual Commercializing Flow Chemistry Summit is back to bridge the gap between academic and industry innovation as your only meeting bringing both technical and strategic flow chemistry intelligence under one roof in Boston this October. \nUniting 100+ Process Development\, Chemistry & Control\, PAT\, CMC\, Continuous Manufacturing and Engineering experts across biopharma\, academia\, CDMO and fine chemical & API organizations for the first time in person\, this is your prime opportunity to turn flow chemistry into industrial applications and implement advanced process control strategies to ensure product quality and meet regulatory expectations. \nFor practical takeaways across technical chemical engineering\, process development\, batch to flow transitions\, novel chemistries\, scale-up\, PAT implementation & more\, reduce your development cycle and enhance operational efficiency by attending the 3rd CFC Summit 2022! \nTo know more visit: https://ter.li/pqcevv
URL:https://www.pharmajournalist.com/event/3rd-commercializing-flow-chemistry-summit-2022/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260516T001518
CREATED:20220613T094420Z
LAST-MODIFIED:20220624T095129Z
UID:34406-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:Innate Killer Summit Europe
DESCRIPTION:The Innate Killer Summit Europe gathers 80+ key European Gamma Delta T\, NK\, and Macrophage developers in October to chase the holy grail of efficacious\, off-the-shelf\, solid tumour immunotherapies through innate cell targeting and engineering. \nSeize your chance to network with innate immune trailblazers from the likes of Sanofi\, Takeda\, Gamida Cell\, Glycostem and Bayer and gain a comprehensive overview of candidates to inform your strategic development and progress the field together with an industry brain trust. \nBridging the gap between the technicalities of early discovery through to process optimisation and leaping regulatory hurdles\, this is the must-attend meeting to accelerate safe and scalable therapies in Europe. \nTo learn more\, visit: www.innate-killer-europe.com
URL:https://www.pharmajournalist.com/event/innate-killer-summit-europe/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260516T001518
CREATED:20220620T112738Z
LAST-MODIFIED:20220620T112738Z
UID:34479-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:Process Development for Cell Therapies Summit
DESCRIPTION:“The Process is the Product” – Drive Process Excellence at the Only Summit Dedicated to Process Development for Cell Therapies \n \nAs momentum continues to build for the cell therapy industry\, process development looms as a huge potential bottleneck to overcome. The inaugural Process Development for Cell Therapies Summit will give you unprecedented access to an industry melting pot of process development tools and experience to drive down cost of goods\, maximize scalability and achieve regulatory compliance. \nJoin your peers who will all be gathering to learn how to identify and plug platform gaps for automation\, global scale-out\, faster phase development\, increased affordability\, and more! \nWith 20+ case studies being presented\, you will come away with tried and tested strategies informed by industry leaders such as BMS\, Kite\, Lyell Immunopharma\, and Immatics Biotechnologies. There is no other event of this kind which is focused specifically on Process Development for Cell Therapy\, delivering case studies to provide actionable insights. \nNow is the time to gather with the industry gurus to unpick shared challenges in process development and share best practices to de-silo the industry and bring better therapies to patients faster. \nFind out more about the meeting\, who’s attending and what you could learn by downloading the latest event guide: https://ter.li/lbtpp0 \nWe look forward to welcoming you to Boston in October!
URL:https://www.pharmajournalist.com/event/process-development-for-cell-therapies-summit/
LOCATION:Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260516T001518
CREATED:20220622T094513Z
LAST-MODIFIED:20220622T094513Z
UID:34491-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy Immunogenicity Summit
DESCRIPTION:The 3rd Annual Gene Therapy Immunogenicity Summit is industry’s definitive forum enabling you to better modulate\, measure and predict the immune response to your gene therapy candidate. \nIn the context of ever-increasing gene therapy clinical activity and uncertainty around challenges posed by immune responses to delivery\, this summit will unite large pharma and innovative biotech’s to ensure that you’re up to speed on the latest approaches to evaluate and overcome pre-existing immunity to AAV vectors\, understand how immune-modulatory strategies can help to ensure efficacy and safety and learn the reality of regulatory expectations around immunological assays. \nIncorporating insights from leading immunological\, bioanalytical\, and translational experts\, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes\, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing clinical mitigation strategies to address immunogenicity. \nWith 35+ industry-based speakers covering pre-clinical and clinical immunogenicity challenges over 2 tracks and 3 packed days of content\, don’t miss your chance to join over 100+ fellow industry experts to network in person and share your research as you seek new and improved ways of predicting immunogenicity in the clinic to ultimately ensure the safety and efficacy of gene therapies. \nTo know more visit: https://ter.li/acp4lt
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-immunogenicity-summit/
LOCATION:The Colonade\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260516T001518
CREATED:20220714T094650Z
LAST-MODIFIED:20220714T094650Z
UID:34667-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:Operationalise: Early Access Programmes Summit Europe
DESCRIPTION:With over 100 early and managed access\, compassionate use\, and named patient programmes running across the continent\, the Operationalise: Early Access Programmes Summit Europe has been carefully curated to help you address difficulties with supply\, logistics and cost\, challenges with navigating European regulations\, and planning and running equitable\, patient-first early access programmes. \nDownload the full event guide to view the world-class speaker faculty of over 20 experienced EAP leaders\, who will be sharing their insights through best-practice case studies. \nImmerse yourself in three days of interactive sessions and discuss your peers’ approaches to involving the patient voice\, engaging different stakeholders\, planning considerations for a successful EAP and more. \nWith a specific focus on real-world case studies and practical applications\, join us to gain a greater understanding and clarity of the end-to-end management of running an early access programme in Europe.
URL:https://www.pharmajournalist.com/event/operationalise-early-access-programmes-summit-europe/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221024
DTEND;VALUE=DATE:20221027
DTSTAMP:20260516T001518
CREATED:20220824T114426Z
LAST-MODIFIED:20220824T114426Z
UID:35001-1666569600-1666828799@www.pharmajournalist.com
SUMMARY:4th TIL Therapies Summit
DESCRIPTION:Commercialization looks set to propel TIL therapy into the spotlight for adoptive cell therapy\, and the 4th TIL Therapies Summit arrives to finally reunite the community in-person this October in Boston\, MA. \nFrom preclinical conversations to the latest developments in streamlined manufacturing this year’s meeting will be the most comprehensive guide for addressing the unique challenges of TIL development to bolster and strengthen your pipelines to achieve your 2022/23 milestones. \nWith 20+ world-class speakers and over 100 senior attendees from around the globe\, join the largest community of TIL-targeted drug development experts for a deep dive into clinical development progress\, lessons learnt and novel strategies to maximize TIL-targeting to recognize and capitalize on this outstanding approach in adoptive cell therapy! \nHere’s your exclusive snapshot of the world class speaker faculty: \n\nMichael Lotze\, Chief Cellular Therapy Officer\, Nurix Therapeutics\nMark Dudley\, Chief Scientific Officer\, InsTIL Bio\nDaniel J Powell Jr\, Associate Professor of Pathology and Laboratory Medicine\, University of Pennsylvania\nParameswaran Hari\, SVP Clinical Sciences\, Iovance Biotherapeutics\nNick Restifo\, Stealth Explorer\, Immunotherapy\nKarrie Wong\, Director Cell Therapy\, KSQ Therapeutics\nAndrew Weinberg\, Chief Scientific Officer\, AgonOx\nJan Ter Meulen\, Chief Scientific Officer\, Obsidian Therapeutics\nTom Henley\, Chief Scientific Officer\, Intima Biosciences\nStephanie Woodall\, Director – Head of Quality\, KSQ Therapeutics\nSylvia Lee\, Associate Professor\, Program in Immunology Clinical Research Division\, Fred Hutchinson Cancer Research Center\nUlrik Cordes\, Founder & Chief Executive Officer\, Cbio\n\nLearn from pioneering trailblazers in TIL development from the National Cancer Institute & University of Pennsylvania alongside leading industry representatives from the likes of Iovance\, Instil Bio and Obsidian Therapeutics. \nAs a host of developers look to bridge to the next generation of TIL therapies\, now is the time to leverage actionable insights to ensure you are set to capitalize on this achieve significant expansion in your development. \nJoin senior leaders from leading biotech\, clinical and academic institutes to discuss data-driven and solution-based approaches to supercharge your TIL therapy towards commercialization. \nTo know more visit: https://ter.li/ygtovu
URL:https://www.pharmajournalist.com/event/4th-til-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:https://ter.li/ygtovu
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221024
DTEND;VALUE=DATE:20221026
DTSTAMP:20260516T001518
CREATED:20220531T110715Z
LAST-MODIFIED:20220531T111046Z
UID:34316-1666569600-1666742399@www.pharmajournalist.com
SUMMARY:SAE Media Group’s 2nd Annual Biosensors for Medical Wearables
DESCRIPTION:SAE Media Group’s 2nd Annual Biosensors for Medical Wearables \n*In collaboration with Medical Design Briefs* \n24th – 25th October 2022 | Boston\, MA\, USA \nSponsored by: Raumedic \nhttp://www.biosensors-medical-wear.com/PJWL \nAdvances in development and therapeutic applications of on-body sensors \nSAE Media Group is proud to present the Biosensors for Medical Wearables Conference\, taking place on the 24th – 25th October 2022. \n \nAs part of SAE Media Group’s leading series of medical device conferences\, this year’s event will be exploring the key drivers and innovations of the wearable medical biosensors landscape with insights into the latest technologies uncovering the therapeutic scope of medical biosensors and the potential of wearable sensors for decentralized diagnostic testing. With growing digital application\, the 2022 agenda will also assess the potential of Artificial Intelligence coupled with sensors and understand how industry is managing digital outcomes. \nChairing the Conference this year will be industry giants James Mault\, MD\, Founder and CEO\, BioIntelliSense\, Inc and Andreas Caduff\, Strategic Advisory Board\, Digital Medicine Society (DiMe). \nThe featured 2022 speakers include: \n\nCarrie Northcott\, Director and Project Lead\, Digital Medicine\, and Translational Imaging (DMTI)\, Early Clinical Development (ECD)\, Pfizer\, Inc\nEric Richardson\, Vice President of Applied Research\, MedRhythms\, Inc.\nJennifer Goldsack\, CEO\, Digital Medicine Society (DiMe)\nSamir Shah\, Director\, AstraZeneca\nTero-Pekka Alastalo\, Chief Medical Officer and General Manager\, US Operations\, CardioSignal Inc\nJohn Ralston\, CEO and Founder\, Neursantys\, Inc.\nChristine Guo\, Chief Scientific c Officer\, ActiGraph\nXina Quan\, Co-Founder and CEO\, PyrAmes\, Inc.\nPierre-Alexandre Fournier\, Co-founder/CEO\, Hexoskin\n\nWhy should you attend? \n\nYou will explore the latest in biosensor technologies for wearable medical devices for therapeutics applications\nYou will uncover the potential of wearable sensors for decentralized diagnostic testing\nYou will delve into the evolving research and technologies to overcome unmet needs of the field including battery technologies for wearable sensors\nYou will assess the growing opportunities and sensor technologies being developed in industry for digital medicine and therapeutics\nYou will engage in platforms and opportunities for sensors coupled with AI and understand how industry are managing digital outcomes\n\nCheckout the early bird offers: \n\nBOOK BY 30TH JUNE AND SAVE $300\nBOOK BY 31ST AUGUST AND SAVE $200\n\nFor more information please contact: \nNikisha Galoria | Marketing Executive | SAE Media Group \nEmail: ngaloria@smi-online.co.uk \nPhone: +44 (0) 20 7827 6164 \nFollow us on: \nLinkedIn: SAE Media Group Pharma \nTwitter: @SAEMGPharma \n#MedicalWearables
URL:https://www.pharmajournalist.com/event/sae-media-groups-2nd-annual-biosensors-for-medical-wearables/
LOCATION:Boston\, MA\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221025
DTEND;VALUE=DATE:20221028
DTSTAMP:20260516T001518
CREATED:20220708T072935Z
LAST-MODIFIED:20220708T072935Z
UID:34589-1666656000-1666915199@www.pharmajournalist.com
SUMMARY:6th Annual Gene Therapy for Rare Disorders Europe Summit 2022
DESCRIPTION:As more and more companies gear up for clinical activity and near approval decisions\, the need to have an in-depth understanding of the regulatory frameworks and how these feed into clinical development and manufacturing processes is as vital as ever. \nThis year’s summit is dedicated to gaining European regulatory clarity to progress efficient and robust gene therapies for rare diseases. By giving voice to pioneering drug developers with success stories to share\, experts in regulatory affairs\, and the regulators themselves\, this meeting is your comprehensive guide to unpicking the thorniest regulatory challenges. \nAcross three carefully curated days\, this streamlined one-track summit will unite key gene therapy leaders from large pharma to ground-breaking biotech\, academics to exciting service providers\, all with the purpose of paving a way forward to successfully launch gene therapy products in Europe. \nTo know more visit: https://bit.ly/3ysiVts
URL:https://www.pharmajournalist.com/event/6th-annual-gene-therapy-for-rare-disorders-europe-summit-2022/
LOCATION:London Marriott Hotel Regents Park\, 128 King Henry’s Road\, London\, NW3 3ST\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221025
DTEND;VALUE=DATE:20221028
DTSTAMP:20260516T001518
CREATED:20220801T092348Z
LAST-MODIFIED:20220801T092348Z
UID:34838-1666656000-1666915199@www.pharmajournalist.com
SUMMARY:7th Annual Computational Drug Development (CDD) for Biologics Summit
DESCRIPTION:Returning to Boston this October\, the 7th Annual Computational Drug Development (CDD) for Biologics Summit will continue to build on the reputation of past meetings while diving into the latest innovations in the industry. This year’s summit will highlight methods and best-practices to extrapolating data & leveraging deep learning for novel\, complex biologics pipeline progression.  \nAcross 3 days\, we will unite leading experts including AbbVie\, GSK\, Amgen\, Genentech\, Takeda & many more to: \n\nOvercome data availability and collection challenges to support machine learning and in silico drug discovery and development for biologics\nRefine high throughput screening methods for novel antibody candidates to shorten your drug development cycles\nAdvance the next generation of computational biology in designing complex antibodies – including multifunctional\, multi-specific antibodies\nEmpower the predictability of protein structures and protein-protein interactions for better drug development\nOptimize your development cycle and decision making using computational data\n\nFind out more – https://ter.li/ec2qbx
URL:https://www.pharmajournalist.com/event/7th-annual-computational-drug-development-cdd-for-biologics-summit/
LOCATION:Boston Marriott Burlington\, One Burlington Mall Road\, Burlington\, MA\, 01803\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221026
DTEND;VALUE=DATE:20221028
DTSTAMP:20260516T001518
CREATED:20220812T122604Z
LAST-MODIFIED:20220812T122604Z
UID:34912-1666742400-1666915199@www.pharmajournalist.com
SUMMARY:Protein Engineering Biocatalysis Congress
DESCRIPTION:The Protein Engineering Biocatalysis Congress is the unique meeting point of industry\, academia and service providers which will enable protein engineering and biocatalysis enthusiasts to industrialize sustainable enzyme products and increase product efficiency globally. \nThis event will highlight case studies on scaling up protein engineering technologies for commercial scale. It is your opportunity to analyze developments in protein engineering for biocatalysis to establish sustainable\, scalable and cost-efficient API manufacturing. \nTo know more visit: www.proteinengineeringglobal.com
URL:https://www.pharmajournalist.com/event/protein-engineering-biocatalysis-congress/
LOCATION:Philadelphia\, USA (venue TBC)
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221101
DTEND;VALUE=DATE:20221104
DTSTAMP:20260516T001518
CREATED:20220727T092002Z
LAST-MODIFIED:20220728T084955Z
UID:34790-1667260800-1667519999@www.pharmajournalist.com
SUMMARY:6th Dermatology Drug Development Summit
DESCRIPTION:The 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases returns to Boston this fall. \nEnsure you join this year’s 150+ expert community in-person to: \n\nUncover recent studies evaluating critical inflammatory and auto-immune pathways\nGain a deeper understanding of promising biologics targeting IL-13\, IL-31\, IL-33\, versus IL-17 associated diseases\nAssess emerging efficacious targeted approaches in the plethora of conditions outside of these pathways.\nObtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet needs such as Hidradenitis Suppurativa\, Vitiligo\, Rare Disease\, and Alopecia Areata\n\nView the event program here: https://ter.li/g3z67z \nRegister here: https://ter.li/vu3tx9 \nIf you have any further questions regarding the summit\, please contact us at info@hansonwade.com.
URL:https://www.pharmajournalist.com/event/6th-dermatology-drug-development-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221107
DTEND;VALUE=DATE:20221110
DTSTAMP:20260516T001518
CREATED:20220825T102329Z
LAST-MODIFIED:20220825T102329Z
UID:35008-1667779200-1668038399@www.pharmajournalist.com
SUMMARY:6th Microbiome Movement – Human Nutrition Summit
DESCRIPTION:Returning to Boston for 2022\, the 6th Microbiome Movement- Human Nutrition Summit is the only industry focused meeting dedicated to exploring the latest innovations\, practical applications and clinical benefits of microbiome targeting food\, beverages and supplements to pave the route to commercial success in the consumer health setting. \nGet up to speed on this dynamic industry with expertise shared from the likes of Bayer\, Postbiotics Plus\, Amazentis and many others\, as the titans of industry unite to: \n\nShowcase the latest scientific findings on the mechanism and functional role of novel microbiome targeting ingredients\nShine a spotlight on the future of postbiotics\, and advance commercialization of microbiome-targeted nutritional interventions\nAdvance commercialization of microbiome-targeted nutritional interventions\n\nWith consumers demanding to have greater control over personal health and wellbeing\, join your community of 100+ industry experts from global CPG companies\, innovative start-ups and biotechs to usher in a new wave of personalised nutrition. \nTo know more visit: https://bit.ly/3clIDZQ
URL:https://www.pharmajournalist.com/event/6th-microbiome-movement-human-nutrition-summit/
LOCATION:TBC
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221109
DTEND;VALUE=DATE:20221112
DTSTAMP:20260516T001518
CREATED:20220728T083732Z
LAST-MODIFIED:20220728T083732Z
UID:34796-1667952000-1668211199@www.pharmajournalist.com
SUMMARY:6th Antifibrotic Drug Development Summit (AFDD)
DESCRIPTION:Returning for the 6th year\, the Antifibrotic Drug Development Summit (AFDD) will host the transferrable insights you need from IPF\, NASH\, CKD and more in one place at one time\, so you can advance the progress of your antifibrotic therapies. \nFrom exploring cellular mechanisms to identify a common fibrotic pathway to bridging the translational gap to prove early therapeutic effectiveness; this unique cross-organ\, cross-disease\, cross-discipline discussion forum is here to transform your fibrosis research. \nJoin 100+ industry super giants from Boehringer Ingelheim\, Genentech\, Gilead\, Pfizer\, Novartis\, and many more in Boston to harness the knowledge you need for your 2022/23 antifibrotic research and drug development. \nTo know more visit: https://ter.li/u60ni5
URL:https://www.pharmajournalist.com/event/6th-antifibrotic-drug-development-summit-afdd/
LOCATION:Crowne Plaza Woburn\, 15 Middlesex Canal Park Rd\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221114
DTEND;VALUE=DATE:20221116
DTSTAMP:20260516T001518
CREATED:20220609T062845Z
LAST-MODIFIED:20220609T062845Z
UID:34376-1668384000-1668556799@www.pharmajournalist.com
SUMMARY:Medical Devices and IVD 2022
DESCRIPTION:SAE Media Group’s Inaugural Conference… \nMedical Devices and IVD 2022\n14 – 15 November 2022\nLondon\, UK\nwww.medicaldevices-ivd.com/PJ \nNavigating The MDR and IVDR and Best Strategies for Compliance  \nSAE Media Group is proud to announce the launch of the Medical Devices and IVD Conference\, taking place on 14 – 15 November 2022 in London\, UK. \n \nThe MDR implementation last May has highlighted issues within the industry that need to be addressed and the upcoming IVDR updates will have a profound impact on the medical device industry\, bringing certain products into regulatory scope that were previously excluded\, introducing new manufacturing requirements\, and increasing the burden for post-market surveillance. \nThe conference will provide insight into the latest updates in EU MDR and IVDR regulations and will discuss strategies for how to best comply with these regulations. In addition\, the conference will consider the evolving regulatory landscape for digital health software. \nBENEFITS OF ATTENDING: \n\nEngage with notified body and competent authority representatives addressing key MDR and IVDR requirements\nGain insights from pharma regulatory experts in compliance and companion diagnostics\nUnderstand the latest guidance on IVD Regulations to overcome common challenges\, in addition to considering evolving global regulations\nExamine post-market expectations for surveillance and vigilance of your medical devices\nDelve into advancements in the digitalisation of medical devices and the regulatory considerations surrounding this\n\nWHO SHOULD ATTEND: \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of: \n\nDevice Manufacturing\nRegulatory Affairs\nIVDR\nMDR\nCMC\nCompliance\nRisk Management\nTraceability\nVigilance\nProduct Development\nPFS\nCombination Products\n\nTo find out more\, please visit: www.medicaldevices-ivd.com/PJ \nEARLY BIRD RATES: \n\nBOOK BY 30TH JUNE TO SAVE £200\nBOOK BY 30TH SEPTEMBER TO SAVE £100\n\nADDITIONAL CONTACT INFORMATION: \n\nE: ngaloria@smi-online.co.uk\nT: +44 (0) 20 7827 6164\n\nFOLLOW US ON: \n\nTwitter: @SAEMGPharma\n\nLinkedIn: SAE Media Group Pharma
URL:https://www.pharmajournalist.com/event/medical-devices-and-ivd-2022/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221116
DTEND;VALUE=DATE:20221118
DTSTAMP:20260516T001518
CREATED:20220805T095510Z
LAST-MODIFIED:20220805T095849Z
UID:34850-1668556800-1668729599@www.pharmajournalist.com
SUMMARY:Microbiome Connect: USA 2022
DESCRIPTION:The 7th Annual Microbiome Connect: USA 2022 is dedicated to showcasing the leading drug development platforms applying microbes\, microbe modulators and microbial-derived components to prevent or treat human diseases or make medical diagnosis. As the first FDA approved microbiome-targeted therapeutic emerges\, drug developers will have the opportunity to benchmark their rational drug platforms\, targeting validated pathways in gastrointestinal\, neurological\, metabolic disorders\, as well as oncology-based indications. Furthermore\, the manufacturing challenges associated with reaching commercialization specific to microbiome-based drugs will be addressed in depth. With talks from Live Biotherapeutic Product manufacturing experts\, including the Head of CBER\, on topics including how to handle USP 61/62\, and achieving co-culturing capabilities. Join us to hear from microbiome biotechs\, pharma voices\, investment bodies\, and more on how to develop robust\, scalable\, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market. \nTo know more visit: www.microbiomeconnectusa.com
URL:https://www.pharmajournalist.com/event/microbiome-connect-usa-2022/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221116
DTEND;VALUE=DATE:20221118
DTSTAMP:20260516T001518
CREATED:20221024T222603Z
LAST-MODIFIED:20221024T222746Z
UID:35596-1668556800-1668729599@www.pharmajournalist.com
SUMMARY:Liquid Biopsy Surveillance & Early Detection Summit
DESCRIPTION:Recognize Disease Hallmarks Earlier for Improved Patient Outcomes \nGain Clarity Across Next Generation Non-Invasive Testing Technologies Revolutionizing Cancer Monitoring\, MRD & Earlier Detection to Support Novel Pre-Metastatic Drug Development with Maximized Access \nIn the wake of new FDA guidance and exciting MRD partnership announcements between Grail & AstraZeneca\, Amgen & Bristol Myers Squibb the liquid biopsy industry is experiencing a paradigm shift. Touted as having the potential to transform clinical practice as we know it\, technical progress and mounting investment in premetastatic applications are creating huge industry-wide excitement for liquid biopsy-based screening & surveillance for novel precision drug development. \nWith technology maturity on the near horizon\, the inaugural Liquid Biopsy Surveillance & Early Detection Summit is your only dedicated platform providing much-needed clarity on the industry’s emerging assays increasingly opening the doors to novel trial design and better patient outcomes. \nAs drug & diagnostic developers look to realize the commercial impact of early detection & MRD while shifting pipelines from the metastatic setting\, here lies your best opportunity to harness game-changing technologies to define leading stratification\, surrogate endpoint\, and regulatory strategies – accelerating the delivery of breakthrough therapies into the clinic. \nProviding a path forward for early detection & surveillance to become a widespread patient reality\, unite with 80+ Translational\, Biomarker\, Clinical\, Regulatory\, Precision Medicine\, Medical Affairs & Diagnostic experts at your only forum prioritizing liquid biopsy applications for earlier intervention. \nTo know more visit: https://ter.li/0kjtfi
URL:https://www.pharmajournalist.com/event/liquid-biopsy-surveillance-early-detection-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221128
DTEND;VALUE=DATE:20221202
DTSTAMP:20260516T001518
CREATED:20220720T112134Z
LAST-MODIFIED:20220720T112134Z
UID:34732-1669593600-1669939199@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy Analytical Development Summit 2022
DESCRIPTION:The past twelve months have culminated in an unprecedented level of excitement\, investment\, and clinical progress within the gene therapy field. As the field strives to strike a delicate balance between safety and efficacy\, in the context of increased regulatory scrutiny and safety challenges\, attending the 4th Annual Gene Therapy Analytical Development as an analytical scientist has never been so important. \nThis year’s summit returns in-person to Boston to reunite 300+ analytical experts in innovative biotech\, pharma and academia to continue to develop resilient\, long-lasting and robust analytical tools to enhance the safety\, quality and efficacy of gene therapy products.   \nWhether you are focusing on specific characterization methods\, enhancing your genome sequencing\, advancing your understanding of full and partial particles\, or advancing your early-stage bioassays\, with 4 tracks\, 8 pre-conference workshops and a post-conference focus day\, the 4th Gene Therapy Analytical Development Summit will encompass all aspects of analytical development\, giving you the chance to address and overcome challenges. \nIf you work in quality control\, quality assurance\, or process development – we’ve listened and we’ve answered. This year’s agenda includes a novel track designed for quality control and process development groups working in gene therapy. Talks include enhancing the knowledge transfer between departments\, bridging between analytical methods with regards to QC/PD\, and enhancing in-process development support. \nWhether you’re working with AAV\, non-viral vectors or lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development. \nTo know more visit: https://ter.li/w2diiu
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-analytical-development-summit-2022/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221128
DTEND;VALUE=DATE:20221201
DTSTAMP:20260516T001518
CREATED:20220819T112405Z
LAST-MODIFIED:20220819T112405Z
UID:34933-1669593600-1669852799@www.pharmajournalist.com
SUMMARY:2nd Rare CNS & Neurodevelopmental Drug Development Summit
DESCRIPTION:Developing New Outcome Measures\, Functional Biomarkers & Clinical Research Regulatory Frameworks for Disease-Modifying Therapeutics Across Neurodevelopmental & Rare\, Genetic CNS Disorders \nWith more clinical data emerging\, neurodevelopmental drug development is advancing from hypotheticals to real-life clinical results\, outcomes\, and functional biomarkers\, catapulting this critical field forwards. \nJoin 100+ peers this November at the 2nd Rare CNS & Neurodevelopmental Drug Development Summit – the only industry dedicated drug development forum for large pharma\, biotech\, academia\, and patient advocacy groups\, paving the way towards symptomatic and successful disease modifying treatments. \nTightly focused on industry progress\, stakeholders will explore ASOs\, gene therapies and small molecules across autistic syndromes and seizure phenotypes at this unique drug sponsor conference. \nDon’t miss out on this definitive opportunity to collaborate with patient groups and gain regulatory clarity on clinical trial design\, endpoints and delivery and toxicity concerns as well as deep diving into functional and molecular biomarkers\, emerging therapeutic targets and translational biology. \nIf you are working towards treatments for rare CNS and neurodevelopmental disorders\, including (but not limited to) Angelman Syndrome\, Rett syndrome\, Fragile X\, Dravet Syndrome and CDKL5 Syndrome or discovering new frontiers in anti-epileptic therapeutics\, this is the platform you need. \nTo know more visit: https://ter.li/9yzux5
URL:https://www.pharmajournalist.com/event/2nd-rare-cns-neurodevelopmental-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260516T001518
CREATED:20220811T093237Z
LAST-MODIFIED:20220811T093237Z
UID:34895-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:4th Inflammasome Therapeutics Summit
DESCRIPTION:The 4th Inflammasome Therapeutics Summit is the only industry-led forum uniting large pharma\, biotechs\, and academic KOLs\, with the common goal of accelerating the practical translation and clinical development of inflammasome-targeted drugs\, which are shaking up the immunology R&D landscape. \nAs the space eagerly awaits data readouts from proof-of-concept trials\, and with more companies than ever before with active inflammasome therapeutic pipelines; this is your opportunity to be involved in interactive discussions on: \n\nDeciphering the intricate mechanisms underlying dysregulated inflammasome signaling within the wider context of the immune system \nOvercoming limitations of preclinical models\, identifying clinically meaningful biomarkers of inflammasome inhibition\, and defining good clinical endpoints \nTaming inflammation and achieving optimized safety profiles using the next frontier for inflammasome-targeted drugs including those targeting NLRP3 and novel targets \nDelving into specific disease groups to demonstrate where inflammasome therapeutics will be most impactful\n\nJoin 120+ fellow peers and industry heavyweights this Fall including NodThera\, Novartis\, Zyversa Therapeutics\, and more\, to build meaningful partnerships and propel the next frontier of inflammasome therapeutics from pipeline development into a clinical and commercial reality. \nAccess the official event guide here to learn more.
URL:https://www.pharmajournalist.com/event/4th-inflammasome-therapeutics-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260516T001518
CREATED:20220811T093818Z
LAST-MODIFIED:20220815T091224Z
UID:34899-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:6th Obesity & NASH Drug Development Summit
DESCRIPTION:The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints\, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders. \n \nWith mounting competition for the market in obesity and all eyes on the next wave of NASH candidates\, the 6th Obesity & NASH Drug Development Summit\, (previously the NASH Summit) is dedicated to reuniting industry leaders in metabolic syndrome to consolidate targets directly implicated in disease pathology and traverse the regulatory hurdles to commercialization. \nJoin 150+ industry pioneers in Boston including pioneers Novo Nordisk\, Eli Lilly\, Boehringer Ingelheim\, Pfizer\, Inventiva\, Regeneron\, FDA\, AstraZeneca\, and more to advance your pipeline towards approved treatment. \nAccess the official event guide here to learn more.
URL:https://www.pharmajournalist.com/event/6th-obesity-nash-drug-development-summit/
LOCATION:Revere Boston Common\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260516T001518
CREATED:20220824T095329Z
LAST-MODIFIED:20220824T114844Z
UID:34996-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:3rd CRISPR 2.0 Summit
DESCRIPTION:Recognized with a Nobel Prize in 2020\, CRISPR has opened the floodgates for a new era of gene editing therapies\, promising to transform genetic disease treatments. With a well-established early field of genomics research\, drug developers and researchers have been busy establishing the next-generation CRISPR toolkit\, including Cas nucleases\, base and prime editing technologies\, and innovative delivery platforms. \nThe 3rd CRISPR 2.0 Summit is devoted to showcasing the latest and greatest innovations by uncovering how the next generation of CRISPR tools are radically enhancing efficacy\, minimizing off-target effects & enabling efficient tissue-specific delivery to help you progress your program into and through the clinic. \nAcross three days of content\, co-designed with 27+ industry thought leaders\, this streamlined one-track summit will unite 100+ key players in the CRISPR space\, from large pharma to ground-breaking biotech\, academics to exciting service providers\, all with the purpose of paving a way forward to market for your CRISPR gene editing program. \nHere’s a snapshot of our 27+ thought leaders: \n\nKiran Musunuru\, Professor of Medicine\, Perelman School of Medicine\, University of Pennsylvania\nAmy Simon\, Chief Medical Officer\, Beam Therapeutics\nJane Grogan\, Chief Scientific Officer\, Graphite Bio\nLiron Walsh\, Head of Development; In Vivo Programs\, Intellia Therapeutics\nJeremy Duffield\, Chief Scientific Officer\, Prime Medicine\nEric B. Kmiec\, Executive Director & Chief Scientific Officer\, Christiana Care Gene Editing Institute\nRafi Emmanuel\, Senior Vice President – Research & Development\, Emendo Biotherapeutics\nJohn Murphy\, Chief Scientific Officer\, Arbor Biotechnologies\nInge Yung-Chih Cheng\, Principal Scientist\, Pfizer\nJoey Riepsaame\, Head of Genome Engineering\, University of Oxford\nRammohan Devulapally\, Principal Scientist\, GenEdit\n\nBe part of the community as we dive deep into: \n\nRefining non-viral tissue targeted CRISPR delivery methods for maximized safety and efficacy\, with help from GenEdit and the latest research from the David Liu Lab.\nFrom bench to bedside: translating basic CRISPR research into a viable therapeutic product\, with Beam Therapeutics\nLeverage the latest base and prime editing technology for enhanced precision treatment of inherited disorders\, with Prime Medicine and UC Irvine.\n\nAnd more! \nJoin this unmissable summit and network experts from the likes of Beam Therapeutics\, The David Liu Lab\, Pfizer\, GenEdit\, AZ\, GSK\, Caribou Biosciences\, Prime Medicine\, Intellia Therapeutics and many more. \nTo know more visit: https://ter.li/vumobp
URL:https://www.pharmajournalist.com/event/3rd-crispr-2-0-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR